High-grade prostate cancer: Elevated PSA is linked to high mortality risk

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.